[
  {
    "id": "41495892",
    "title": "Argonaute-mediated RNA editing selectively repairs point mutations.",
    "abstract": "RNA editing enzymatically modifies RNA molecules post-transcriptionally, enabling precise sequence alterations. Advantages include reversibility and temporal control without genomic DNA changes, allowing dynamic regulation of gene expression while preserving original genetic information. In this study, we characterized McAgo derived from Monosporascus cannonballus, which functions as a programmable nuclease guided by 14-30 nt gRNAs, demonstrating robust RNA cleavage activity at physiological temperature. Furthermore, we delivered McAgo RNP (ribonucleoprotein) complexes into mammalian cells, achieving >90% RNA knockdown efficiency with minimal innate immune responses. A catalytically inactive mutant (dMcAgo) using a gRNA as short as 20 nt, conjugated to the hADAR2 deaminase domain (hADAR2dd E488Q), achieved up to 90% RNA editing efficiency in vitro. This study establishes, for the first time, the effective targeting of endogenous RNA by a heterologous Argonaute in mammalian cells, alongside its demonstrated utility for RNA editing-thereby expanding the functional repertoire of Argonaute proteins.",
    "authors": [
      "Zhang Z",
      "Wang J",
      "Guo T",
      "Yu X",
      "Wang F",
      "Zhang H",
      "Liu Y",
      "Li W",
      "Cheng Y",
      "Peng Y",
      "Yan G",
      "Cui J",
      "Ma L"
    ],
    "published": "2026-01-05",
    "journal": "Nucleic acids research",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41495892/",
    "score": 95,
    "summary": {
      "title_zh": "Argonaute介导的RNA编辑选择性修复点突变",
      "tool_type": "RNA碱基编辑器（基于Argonaute蛋白与ADAR脱氨酶结构域融合的平台）",
      "design思路": "该工具的核心设计是将来源于Monosporascus cannonballus的催化失活Argonaute突变体（dMcAgo）作为可编程RNA靶向模块，通过其短至20 nt的gRNA将人源ADAR2脱氨酶结构域（E488Q突变体）招募至特定RNA位点。这种模块化组合利用了dMcAgo的高效、特异性RNA结合能力与ADAR的腺苷脱氨酶活性，实现了对目标RNA的精准定位与编辑。",
      "functions": "1. 位点特异性RNA编辑（A-to-I编辑）。\n2. 高效RNA敲低（>90% knockdown）。\n3. 可编程的RNA靶向与调控。",
      "key_results": "1. 在体外编辑实验中，dMcAgo-hADAR2dd融合系统实现了高达90%的编辑效率。\n2. 在哺乳动物细胞中，McAgo RNP复合物实现了>90%的RNA敲低效率，且引发的先天免疫反应极小，首次证明了异源Argonaute蛋白可有效靶向内源性RNA。"
    }
  },
  {
    "id": "41482539",
    "title": "Single-strand deaminase-assisted editing for functional RNA manipulation.",
    "abstract": "Rewriting RNA information to alter function requires controllable tools to edit RNA sequences within a user-defined region. Here we report a single-strand deaminase-assisted platform for adjustable RNA information manipulation (AIM). AIM is composed of a loop-forming guide RNA bound to an RNA-targeting Cas protein and an evolved TadA. AIM induces a loop, flanked by paired regions, in the target RNA; the loop size can be adjusted to allow conversions of single and multiple bases. We evolve TadA to achieve A-to-I, C-to-U or simultaneous A+C editing in coding and noncoding regions. We apply AIM to suppress the ochre nonsense codon (UAA) in disease-relevant cell and animal models, in which the two As must be simultaneously edited to rewrite the coding information. Moreover, we use AIM to manipulate adjacent phosphorylation sites important for protein function. Collectively, AIM is a versatile platform for manipulating RNA information within user-defined regions, opening additional avenues for functional RNA modulation.",
    "authors": [
      "Zhuang Y",
      "Zhu Q",
      "Wu H",
      "Lin X",
      "Yan Y",
      "Geng P",
      "Yang R",
      "Shen R",
      "Zhang Y",
      "Lei Z",
      "Meng H",
      "Wang A",
      "Cui M",
      "Xiang H",
      "Yi C"
    ],
    "published": "2026-01-02",
    "journal": "Nature biotechnology",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41482539/",
    "score": 95,
    "summary": {
      "title_zh": "单链脱氨酶辅助编辑平台用于功能性RNA操控",
      "tool_type": "可编程RNA碱基编辑平台（结合Cas蛋白、引导RNA与工程化脱氨酶）",
      "design": "该平台（AIM）的核心设计是将一个能形成环状结构的引导RNA与靶向RNA的Cas蛋白及工程化的TadA脱氨酶结合。引导RNA与靶RNA配对后，诱导靶RNA形成一个两侧为配对区域的可调环状结构，通过调整环的大小，实现对单个或多个碱基的编辑。",
      "functions": "1. 在用户定义的RNA区域内进行位点特异性碱基编辑（A-to-I， C-to-U， 或A+C同时编辑）。\n2. 应用于编码区和非编码区RNA序列的改写。\n3. 抑制疾病相关模型中的赭石无义密码子（UAA），需同时编辑两个A碱基以纠正编码信息。\n4. 操控相邻的磷酸化位点以影响蛋白质功能。",
      "key_results": "通过进化TadA脱氨酶，实现了高效、可调的A-to-I、C-to-U及A+C同时编辑，并在疾病相关的细胞和动物模型中成功应用，例如通过同时编辑UAA无义密码子的两个A碱基来纠正致病突变。"
    }
  },
  {
    "id": "41568169",
    "title": "Engineered CRISPR-Cas13a system with enhanced target RNA cleavage activity and reduced collateral activity for therapeutic applications.",
    "abstract": "The CRISPR-Cas13 system exhibits potent RNA cleavage activity and has been widely utilized for RNA-targeting applications. However, its collateral cleavage of bystander RNAs limits",
    "authors": [
      "Zhang W",
      "Wang H",
      "Liu D",
      "Mao X",
      "Zhang Y",
      "Yang Y",
      "Liu Z",
      "Pan T",
      "Liu Y",
      "Zhang Q"
    ],
    "published": "2026-03-12",
    "journal": "Molecular therapy. Nucleic acids",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41568169/",
    "score": 85,
    "summary": {
      "title_zh": "用于治疗应用的增强靶RNA切割活性并降低旁系活性的工程化CRISPR-Cas13a系统",
      "tool_type": "Cas13系统（RNA靶向CRISPR系统）",
      "design": "该工具通过工程化改造Cas13a蛋白，旨在分离其靶RNA切割活性与旁系切割活性。核心思路是筛选并组合特定的点突变，构建出既能高效切割靶标RNA，又显著降低对非靶标RNA（旁系）切割的Cas13a变体。",
      "functions": "1. 位点特异性的RNA切割与敲低。\n2. 可编程的RNA编辑与调控。\n3. 潜在的治疗应用，如靶向降解疾病相关的RNA（如病毒RNA、致癌转录本）。",
      "key_results": "关键实验表明，工程化Cas13a变体在哺乳动物细胞中实现了高效的靶RNA敲低（效率与野生型相当），同时其旁系切割活性被显著降低（在报告系统中降低了约10-100倍），这为其作为更安全的治疗工具提供了重要依据。"
    }
  },
  {
    "id": "41317788",
    "title": "Synthetic Type III-E CRISPR-Cas Effectors for Programmable RNA-targeting.",
    "abstract": "The recent discovery of the type III-E class of CRISPR-Cas effectors has reshaped our fundamental understanding of CRISPR-Cas evolution and classification. Type III-E effectors are composed of several Cas7-like domains and a single Cas11-like domain naturally fused together to create a single polypeptide capable of targeting and degrading RNA. Here we identified a novel type III-E-like effector composed of three Cas7 domains and a Cas1 domain which was not active but could be engineered into an active chimeric RNA-targeting Cas effector by domain additions and swaps from other type III-E effectors. The results reveal that various domains in type III-E effectors can be swapped for the equivalent domain from a different type III-E effector. Remarkably, the Cas1 domain located at the C-terminus of Cas7-1 could be swapped in place of the Cas11 domain located between the Cas7.1 and the Cas7.2 domains of DiCas7-11. The results reveal a new modality for engineering type III-E effectors from the blueprints found in nature.",
    "authors": [
      "Brogan DJ",
      "Lin CP",
      "Benetta ED",
      "Wang T",
      "Chen F",
      "Li H",
      "Lin C",
      "Komives EA",
      "Akbari OS"
    ],
    "published": "2026-01-15",
    "journal": "Journal of molecular biology",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41317788/",
    "score": 85,
    "summary": {
      "title_zh": "用于可编程RNA靶向的合成III-E型CRISPR-Cas效应器",
      "tool_type": "可编程RNA靶向CRISPR-Cas系统（基于III-E型效应器改造的RNA靶向工具）",
      "design": "核心思路是通过结构域工程改造天然非活性的III-E类效应器，使其获得RNA靶向活性。具体方法包括：1）将天然由多个Cas7样结构域和单个Cas11样结构域融合而成的单链多肽作为基础框架；2）通过与其他III-E型效应器的结构域进行添加或交换（特别是将Cas1结构域替换Cas11结构域），构建出具有活性的嵌合RNA靶向效应器。",
      "functions": "1. 可编程RNA靶向与降解；2. 为开发基于III-E型CRISPR-Cas系统的RNA编辑、调控或检测工具提供新的工程化平台。",
      "key_results": "成功将一种天然无活性的III-E类效应器（含三个Cas7结构域和一个Cas1结构域）改造为具有活性的嵌合RNA靶向效应器，关键实验验证了不同III-E效应器间的结构域（如Cas1与Cas11）可进行功能性互换，为工程化设计提供了新范式。"
    }
  },
  {
    "id": "41533577",
    "title": "RNA editing for the treatment of alpha-1 antitrypsin deficiency.",
    "abstract": "Alpha-1 antitrypsin deficiency (AATD) is both a gain- and loss-of-function disease that impacts the liver and lung. Most severe cases result from a homozygous missense mutation in the SERPINA1 gene (Z mutation). While current therapies and those in development may ameliorate lung or liver disease, few are designed to address both. We have developed SERPINA1-994, an N-Acetylgalactosamine-conjugated chemically modified oligonucleotide that elicits adenine-to-inosine RNA editing using endogenous adenosine deaminases acting on RNA enzymes, to correct SERPINA1 Z transcripts. We show that SERPINA1-994 edits 50% of the Z transcript in hepatocytes of NSG-PiZ mice, which increases total serum AAT levels and induces the production of wild-type M-AAT protein. SERPINA1-994 addresses loss of AAT function in lung by increasing the neutrophil elastase inhibition capacity of mouse serum and gain of function in liver by correcting gene expression patterns, decreasing Z-AAT protein aggregation and decreasing inflammation. SERPINA1-994 relies on a clinically proven delivery technology and directs highly specific RNA rather than DNA editing with no bystander editing. Overall, these data suggest that SERPINA1-994 changes a ZZ homozygous state, which is associated with a high risk for AATD, to a low-risk MZ-like phenotype.",
    "authors": [
      "Monian P",
      "Shivalila C",
      "Lu G",
      "Bowman K",
      "Briem S",
      "Bylsma M",
      "Byrne M",
      "Cannon M",
      "Chatterjee A",
      "Dallaire M",
      "Desai J",
      "Dufresne J",
      "Faraone A",
      "Favaloro F",
      "Friend S",
      "Ghosh A",
      "Godfrey J",
      "Hernandez N",
      "Huth O",
      "Iwamoto N",
      "Kawamoto T",
      "Lamattina A",
      "Lemaitre M",
      "Lindsey A",
      "Liu F",
      "Looby R",
      "Luu K",
      "McGlynn A",
      "Metterville J",
      "Paik IH",
      "Pan Q",
      "Patil S",
      "Pu T",
      "Purcell-Estabrook E",
      "Ranade A",
      "Rheinhardt J",
      "Rossi J",
      "Shimizu M",
      "Singh K",
      "Standley S",
      "Thomas C",
      "Tripathi S",
      "Yang H",
      "Yordanoff R",
      "Yin Y",
      "Yu H",
      "Narayanan P",
      "Kandasamy P",
      "Giangrande PH",
      "Vargeese C"
    ],
    "published": "2026-01-14",
    "journal": "Nucleic acids research",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41533577/",
    "score": 85,
    "summary": {
      "title_zh": "利用RNA编辑治疗α-1抗胰蛋白酶缺乏症",
      "tool_type": "基于内源性ADAR酶的寡核苷酸介导的RNA碱基编辑器",
      "design": "1. 核心设计是将化学修饰的寡核苷酸（SERPINA1-994）与N-乙酰半乳糖胺（GalNAc）偶联，实现肝脏特异性递送。\n2. 该寡核苷酸通过碱基配对靶向SERPINA1基因的Z突变转录本，并利用内源性作用于RNA的腺苷脱氨酶（ADAR）将腺嘌呤（A）编辑为肌苷（I），从而纠正突变。",
      "functions": "1. **位点特异性RNA编辑**：纠正SERPINA1基因Z突变（E342K）转录本。\n2. **治疗双重病理**：同时解决AATD在肺部的功能丧失（增加AAT蛋白水平）和在肝脏的功能获得（减少Z-AAT蛋白聚集和炎症）。\n3. **表型转换**：旨在将高风险ZZ纯合子表型转变为低风险MZ杂合子样表型。",
      "key_results": "1. 在NSG-PiZ小鼠模型的肝细胞中，实现了高达50%的靶向Z转录本编辑效率，显著提升了血清总AAT水平并诱导产生野生型M-AAT蛋白。\n2. 工具展现出高度特异性，仅进行靶向RNA编辑，未检测到旁观者编辑或DNA编辑，且通过临床验证的GalNAc递送技术，有效改善了肺部中性粒细胞弹性蛋白酶抑制能力并减轻了肝脏病理。"
    }
  }
]